| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Objectives: Acute promyelocytic leukemia (APL) is a relatively rare disease ? it represents about 7-10% of adult AML in Middle Europe. However, it is a very important subgroup with respect to the improvements in treatment that have been achieved. Before ATRA introduction APL had a very poor prognosis, caused by serious complications, mainly fatal intracerebral bleeding. Methods: The retrospective analysis of group of consecutive 37 APL patients treated with ATRA based therapy in 1993-2007 was performed. Results: The median of age at diagnosis was 46 years (19-73), M:F = 17:20. Most of patients (88%) were treated in accordance with EORTC 06952 protocol. All but one treated patients achieved complete molecular remission (97%). Long-term overall survival (OS) is 72%, OS in the CR group (OSCR) is 81%. 2 out of 3 relapsed patients achieved long-lasting second remission after ATRA based chemotherapy in the first patient and autologous transplantation in the second one. We have not seen any patient with
- Objectives: Acute promyelocytic leukemia (APL) is a relatively rare disease ? it represents about 7-10% of adult AML in Middle Europe. However, it is a very important subgroup with respect to the improvements in treatment that have been achieved. Before ATRA introduction APL had a very poor prognosis, caused by serious complications, mainly fatal intracerebral bleeding. Methods: The retrospective analysis of group of consecutive 37 APL patients treated with ATRA based therapy in 1993-2007 was performed. Results: The median of age at diagnosis was 46 years (19-73), M:F = 17:20. Most of patients (88%) were treated in accordance with EORTC 06952 protocol. All but one treated patients achieved complete molecular remission (97%). Long-term overall survival (OS) is 72%, OS in the CR group (OSCR) is 81%. 2 out of 3 relapsed patients achieved long-lasting second remission after ATRA based chemotherapy in the first patient and autologous transplantation in the second one. We have not seen any patient with (en)
- Objectives: Acute promyelocytic leukemia (APL) is a relatively rare disease ? it represents about 7-10% of adult AML in Middle Europe. However, it is a very important subgroup with respect to the improvements in treatment that have been achieved. Before ATRA introduction APL had a very poor prognosis, caused by serious complications, mainly fatal intracerebral bleeding. Methods: The retrospective analysis of group of consecutive 37 APL patients treated with ATRA based therapy in 1993-2007 was performed. Results: The median of age at diagnosis was 46 years (19-73), M:F = 17:20. Most of patients (88%) were treated in accordance with EORTC 06952 protocol. All but one treated patients achieved complete molecular remission (97%). Long-term overall survival (OS) is 72%, OS in the CR group (OSCR) is 81%. 2 out of 3 relapsed patients achieved long-lasting second remission after ATRA based chemotherapy in the first patient and autologous transplantation in the second one. We have not seen any patient with (cs)
|
| Title
| - All-transretioic acis(ATRA) in the treatment of acute promyelocytic leukemia - 15 years of single centre experience
- All-transretioic acis(ATRA) in the treatment of acute promyelocytic leukemia - 15 years of single centre experience (en)
- All-transretioic acis(ATRA) in the treatment of acute promyelocytic leukemia - 15 years of single centre experience (cs)
|
| skos:prefLabel
| - All-transretioic acis(ATRA) in the treatment of acute promyelocytic leukemia - 15 years of single centre experience
- All-transretioic acis(ATRA) in the treatment of acute promyelocytic leukemia - 15 years of single centre experience (en)
- All-transretioic acis(ATRA) in the treatment of acute promyelocytic leukemia - 15 years of single centre experience (cs)
|
| skos:notation
| - RIV/61989592:15110/07:00004442!RIV08-MSM-15110___
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/07:00004442
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Acute promyelocytic leukemia (APL); All-transretioic acis(ATRA) (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Faber, Edgar
- Hubáček, Jaromír
- Indrák, Karel
- Jarošová, Marie
- Pikalová, Zuzana
- Raida, Luděk
- Szotkowski, Tomáš
|
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)